Details

Autor(en) / Beteiligte

• ROMAN-GOMEZ, Jose
• AGIRRE, Xabier
• MARTIN, Vanesa
• CASTILLEJO, Juan Antonio
• BANDRES, Eva
• CALASANZ, Maria José
• SIEBERT, Reiner
• HEINIGER, Anabel
• TORRES, Antonio
• PROSPER, Felipe
• JIMENEZ-VELASCO, Antonio
• ARQUEROS, Victor
• VILAS-ZORNOZA, Amaia
• RODRIGUEZ-OTERO, Paula
• MARTIN-SUBERO, Inaki
• GARATE, Leire
• CORDEU, Lucia
• SAN JOSE-ENERIZ, Edurne

Titel

Epigenetic Regulation of MicroRNAs in Acute Lymphoblastic Leukemia

Ist Teil von

• Journal of clinical oncology, 2009-03, Vol.27 (8), p.1316-1322

Ort / Verlag

Alexandria, VA: American Society of Clinical Oncology

Erscheinungsjahr

2009

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• To identify microRNAs (miRNAs) epigenetically regulated in acute lymphoblastic leukemia (ALL). We first examined ALL-derived cell lines for the presence of abnormal levels of two different histone modifications (trimethylation of H3 lysine 4 [K4H3me3] and dimethylation of H3 lysine 9 [K9H3me2]) in the 5'UTR regions around CpG islands of 78 miRNAs by chromatin immunoprecipitation (ChIP)-on-ChIP analysis. Methylation status (methylation-specific polymerase chain reaction [PCR]) and expression (quantitative PCR) of miRNAs showing a pattern of histone modifications linked to a closed chromatin structure were analyzed in a panel of six ALL cell lines and in 353 ALL patients. CpG islands around 13 miRNAs disclosed high levels of K9H3me2 and/or low levels of K4H3me3, a pattern of histone modifications underlying a closed chromatin structure associated with repressive gene expression. Complete consistency in the correlation between both histone marks, the presence of DNA methylation around these miRNAs, and their expression patterns was confirmed in the six ALL cell lines. Treatment with 5-Aza-2'-deoxycytidine upregulated the expression levels of these genes, suggesting that epigenetic mechanisms deregulate the expression of these miRNAs. A total of 65% of the ALL samples had at least one miRNA methylated (methylated group). Estimated disease-free survival (DFS) and overall survival (OS) at 14 years were 78% and 71% for nonmethylated patients and 24% and 28% for methylated patients (P = .00001 for both). Multivariate analysis demonstrated that methylation profile was an independent prognostic factor for predicting DFS (P = .0001) and OS (P = .0001). Aberrant miRNA methylation is a common phenomenon in ALL that affects the clinical outcome of these patients.